In vitro activity of the fluoroquinolone compounds

Effects of Magnesium, Calcium, and Aluminum Chelation on Fluoroquinolone Absorption Rate and Bioavailability: A Computational Study

Fluoroquinolones (FQs) are a widespread class of broad-spectrum antibiotics prescribed as a first line of defense, and, in some cases, as the only treatment against bacterial infection. However, when administered orally, reduced absorption and bioavailability can occur due to chelation in the gastrointestinal tract (GIT) with multivalent metal cations acquired from diet, coadministered compounds (sucralfate, didanosine), or drug formulation. Predicting the extent to which this interaction reduces in vivo antibiotic absorption and systemic exposure remains desirable yet challenging. In this study, we focus on quinolone interactions with magnesium, calcium and aluminum as found in dietary supplements, antacids (Maalox) orally administered therapies (sucralfate, didanosine). The effect of FQ-metal complexation on absorption rate was investigated through a combined molecular and pharmacokinetic (PK) modeling study. Quantum mechanical calculations elucidated FQ-metal binding energies, which were leveraged to predict the magnitude of reduced bioavailability via a quantitative structure-property relationship (QSPR). This work will help inform clinical FQ formulation design, alert to possible dietary effects, and shed light on drug-drug interactions resulting from coadministration at an earlier stage in the drug development pipeline.

The antibiotic susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne

We studied the susceptibility of antimicrobial agents to Propionibacterium acnes (P. acnes) and Staphylococcus epidermidis (S. epidermidis) isolated from acne patients. We measured the minimum inhibitory concentrations (MICs) of the following five drugs: roxithromycin (RXM), erythromycin (EM), clindamycin (CLDM), minocycline (MINO) and ofloxacin (OFLX), which are frequently used to treat acne and skin infections. We found many resistant strains of S. epidermidis and some resistant strains of P. acnes. There was a correlation between the resistance of S. epidermidis and the former therapy for acne, but no distinct correlation between the resistance of P. acnes and the former therapy for acne.

In vitro activity of nine fluoroquinolone antibiotics against 200 strains of enterococci

The in vitro activity of nine fluoroquinolones against 200 recent clinical isolates of enterococci was evaluated. The relative activity was WIN57273 > sparfloxacin > ciprofloxacin, temafloxacin > ofloxacin > fleroxacin, lomefloxacin, norfloxacin > enoxacin. Susceptibility to gentamicin or streptomycin did not influence the activity of the fluoroquinolones.

New therapeutic agents in veterinary dermatology

The rapid development of therapeutic agents will continue to provide veterinarians with new options in treating dermatologic disease. However, we must not overlook the possibility of new applications for older drugs. Ideally, before a drug can be recommended for routine use, it should be evaluated for safety and efficacy using unbiased scientific methods. Unfortunately, this type of testing is expensive and may take years to complete. Veterinarians faced with managing a difficult skin disease may have to make decisions based on anecdotal information or case reports. The importance of good client communication cannot be overemphasized. The veterinarian must explain the benefits and risks of each therapeutic option. A written informed consent statement is advisable when using a drug in a manner not approved by the FDA.

Quinolones and the gastrointestinal tract

A number of studies have evaluated the efficacy of the new fluoroquinolones for therapy of bacterial enteric diseases and for prevention of gram-negative sepsis in granulocytopenic patients. The success of the quinolones in these settings is related to several special features of these agents, including their spectrum of activity and high fecal levels, which are in turn reflected in their effect on the gastrointestinal flora. Other factors that are important, particularly for invasive disease such as typhoid fever and shigellosis, include good intracellular and bowel wall penetration, and lymph node and systemic drug concentrations many times higher than the MICs of the causative organisms. This article reviews the factors that contribute to the changes in fecal flora, and the results of clinical studies in patients with diarrhea, granulocytopenic patients, and patients with selected other infections of, or related to, the gastrointestinal tract.